Jeff Martin
Stock Analyst at Roth Capital
(4.33)
# 341
Out of 4,931 analysts
61
Total ratings
60%
Success rate
14.15%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSP Insperity | Maintains: Buy | $85 → $74 | $52.20 | +41.76% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $19.05 | +41.73% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $3.87 | +29.20% | 1 | May 14, 2025 | |
| PERI Perion Network | Upgrades: Buy | $9 → $14 | $9.97 | +40.49% | 8 | May 14, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $223.18 | +9.78% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $6.07 | +48.27% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $46.86 | -3.97% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $20.90 | +43.54% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $35.53 | +21.02% | 5 | Aug 8, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.39 | +412,951.27% | 2 | Nov 15, 2017 |
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $52.20
Upside: +41.76%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $19.05
Upside: +41.73%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $3.87
Upside: +29.20%
Perion Network
May 14, 2025
Upgrades: Buy
Price Target: $9 → $14
Current: $9.97
Upside: +40.49%
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $223.18
Upside: +9.78%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $6.07
Upside: +48.27%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $46.86
Upside: -3.97%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $20.90
Upside: +43.54%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $35.53
Upside: +21.02%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.39
Upside: +412,951.27%